Thyroid Hormone T4 (Thyroxine) Suppression
| Property | Information |
|---|---|
| Drug Name | Thyroid Hormone T4 Suppression Therapy |
| FDA Approval | No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved) |
| Used for | Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status |
| Clinical Trial Phase | Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Carefully monitored to avoid clinical symptoms of hypothyroidism; includes potential for fatigue if not properly managed |
| OS without | Not specified |
| OS with | In early studies, hypothyroid patients showed median survival of 10.1 months compared to 3.1 months in non-hypothyroid patients. Remarkable long-term survivors in informal cohort studies with advanced cancer, including glioblastoma patients surviving 36 and 48 months.Property "Has OS with" (as page type) with input value "In early studies, hypothyroid patients showed median survival of 10.1 months compared to 3.1 months in non-hypothyroid patients. Remarkable long-term survivors in informal cohort studies with advanced cancer, including glioblastoma patients surviving 36 and 48 months." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process. |
| PFS without | Not specified |
| PFS with | Not specifically documented; focus on overall survival improvements |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
Links: NCT02654041
From Ben Williams Book: Not specified
